Previous 10 | Next 10 |
CLEVELAND, March 18, 2024 (GLOBE NEWSWIRE) -- Abeona Therapeutics Inc. (Nasdaq: ABEO) today reported financial results for the full year of 2023 and provided an update on progress toward achieving key corporate objectives. Abeona also announced today that the U.S. Food and Drug Administrati...
2024-02-07 10:31:12 ET More on Abeona Therapeutics Abeona issues update on FDA market application for pz-cel Abeona Therapeutics announces $50M credit facility Seeking Alpha’s Quant Rating on Abeona Therapeutics Historical earnings data for Abeona Ther...
2024-02-01 11:48:30 ET More on Abeona Therapeutics Abeona Therapeutics Inc. (ABEO) Q3 2023 Earnings Call Transcript Abeona Therapeutics announces $50M credit facility Abeona shares jump after FDA priority review for epidermolysis bullosa drug Seeking Alpha...
- On track for PDUFA target action date of May 25, 2024 - CLEVELAND, Feb. 01, 2024 (GLOBE NEWSWIRE) -- Abeona Therapeutics Inc. (Nasdaq: ABEO) today announced, as part of the review process by the U.S. Food and Drug Administration (FDA) for the Biologics License Application (BLA) for pz-c...
2024-01-08 07:54:50 ET More on Abeona Therapeutics Abeona Therapeutics Inc. (ABEO) Q3 2023 Earnings Call Transcript Abeona shares jump after FDA priority review for epidermolysis bullosa drug Abeona Therapeutics GAAP EPS of -$0.48 beats by $0.05 Seeking Alpha...
CLEVELAND, Jan. 08, 2024 (GLOBE NEWSWIRE) -- Abeona Therapeutics Inc. (Nasdaq: ABEO) today announced that it has entered into a $50 million credit facility with the Avenue Venture Opportunities Fund, L.P. The credit agreement, which has a term of three and a half years, includes a first tranche o...
2023-11-27 07:50:10 ET More on Abeona Therapeutics Abeona Therapeutics Inc. (ABEO) Q3 2023 Earnings Call Transcript Abeona Therapeutics GAAP EPS of -$0.48 beats by $0.05 Abeona submits FDA market application for rare skin disorder drug Seeking Alpha’s ...
- PDUFA target action date is May 25, 2024 - - FDA does not currently plan to hold Advisory Committee meeting for pz-cel BLA - CLEVELAND, Nov. 27, 2023 (GLOBE NEWSWIRE) -- Abeona Therapeutics Inc. (Nasdaq: ABEO) today announced that the U.S. Food and Drug Administration (FDA) has ac...
2023-11-16 16:26:04 ET Abeona Therapeutics Inc. (ABEO) Q3 2023 Results Conference Call November 13, 2023 8:30 AM ET Company Participants Greg Gin - Vice President of Investor Relations & Corporate Communications Vishwas Seshadri - President, CEO and Director ...
2023-11-13 07:48:31 ET More on Abeona Therapeutics Abeona submits FDA market application for rare skin disorder drug Abeona plans marketing submission for lead asset after FDA meeting Seeking Alpha’s Quant Rating on Abeona Therapeutics Historical earni...
News, Short Squeeze, Breakout and More Instantly...
Abeona Therapeutics Inc. Company Name:
ABEO Stock Symbol:
NASDAQ Market:
Abeona Therapeutics Inc. Website:
CLEVELAND and LONDON, July 11, 2024 (GLOBE NEWSWIRE) -- Abeona Therapeutics Inc. (Nasdaq: ABEO), a cell and gene therapy company with proprietary adeno-associated virus (AAV)-based capsids, and Beacon Therapeutics, an ophthalmic gene therapy company and Syncona portfolio company, today announced ...
CLEVELAND, July 08, 2024 (GLOBE NEWSWIRE) -- Abeona Therapeutics Inc. (Nasdaq: ABEO) today announced that Abeona’s Chief Executive Officer, Vish Seshadri, Ph.D., M.B.A., and Chief Commercial Officer, Madhav Vasanthavada, Ph.D., M.B.A., will participate in a virtual fireside chat at the Sti...
2024-07-03 07:15:03 ET H.C. Wainwright analyst issues BUY recommendation for ABEO on July 3, 2024 06:07AM ET. ABEO was trading at $4.12 at issue of the analyst recommendation. The overall analyst consensus : BUY. Current analyst recommendations are : 1 - Buy recommendati...